Impaired Coronary and Renal Vascular Function in Spontaneously Type 2 Diabetic Leptin-Deficient Mice

PLoS One. 2015 Jun 22;10(6):e0130648. doi: 10.1371/journal.pone.0130648. eCollection 2015.

Abstract

Background: Type 2 diabetes is associated with macro- and microvascular complications in man. Microvascular dysfunction affects both cardiac and renal function and is now recognized as a main driver of cardiovascular mortality and morbidity. However, progression of microvascular dysfunction in experimental models is often obscured by macrovascular pathology and consequently demanding to study. The obese type 2 diabetic leptin-deficient (ob/ob) mouse lacks macrovascular complications, i.e. occlusive atherosclerotic disease, and may therefore be a potential model for microvascular dysfunction. The present study aimed to test the hypothesis that these mice with an insulin resistant phenotype might display microvascular dysfunction in both coronary and renal vascular beds.

Methods and results: In this study we used non-invasive Doppler ultrasound imaging to characterize microvascular dysfunction during the progression of diabetes in ob/ob mice. Impaired coronary flow velocity reserve was observed in the ob/ob mice at 16 and 21 weeks of age compared to lean controls. In addition, renal resistivity index as well as pulsatility index was higher in the ob/ob mice at 21 weeks compared to lean controls. Moreover, plasma L-arginine was lower in ob/ob mice, while asymmetric dimethylarginine was unaltered. Furthermore, a decrease in renal vascular density was observed in the ob/ob mice.

Conclusion: In parallel to previously described metabolic disturbances, the leptin-deficient ob/ob mice also display cardiac and renal microvascular dysfunction. This model may therefore be suitable for translational, mechanistic and interventional studies to improve the understanding of microvascular complications in type 2 diabetes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Coronary Circulation*
  • Diabetes Mellitus, Type 2 / diagnostic imaging*
  • Diabetes Mellitus, Type 2 / genetics
  • Laser-Doppler Flowmetry
  • Leptin / deficiency*
  • Leptin / genetics
  • Male
  • Mice
  • Renal Circulation*
  • Ultrasonography

Substances

  • Leptin

Grants and funding

Agreement concerning research and education of doctors, Sahlgrenska University Hospital, Gothenburg Sweden together with AstraZeneca are the funders of all work. Co-authors Julia Grönros, Suvi E Heinonen, Tasso Miliotis, Karin Jennbacken, Alan Sabirsh, Anette Ericsson, Ann-Cathrine Jönsson-Rylander and Li-ming Gan are employed by AstraZeneca R&D Mölndal. First author and co-author Sara Svedlund is supported by Agreement concerning research and education of doctors. The funder AstraZeneca provided support in the form of salaries for authors JG, SEH, TM, KJ, AS, AE, ACJR and LMG but did not have any additional role in the study design, data collection and analysis, or preparation of the manuscript. The decision to publish was made by an internal AstraZeneca review of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.